

## FEP 7.01.126 Image-Guided Minimally Invasive Lumbar Decompression for Spinal Stenosis

**Effective Date:** July 15, 2018

**Related Policies:**

7.01.107 Interspinous and Interlaminar Stabilization/Distraktion Devices (Spacers)

## Image-Guided Minimally Invasive Lumbar Decompression for Spinal Stenosis

### Description

Image-guided minimally invasive lumbar decompression (IG-MLD) describes a percutaneous procedure for decompression of the central spinal canal in patients with spinal stenosis and hypertrophy of the ligamentum flavum. In this procedure, a specialized cannula and surgical tools (mild®) are used under fluoroscopic guidance for bone and tissue sculpting near the spinal canal. IG-MLD is proposed as an alternative to existing posterior decompression procedures.

### FDA REGULATORY STATUS

In 2006, the X-Sten MILD Tool Kit now the mild® device kit (X-Sten Corp. renamed Vertos Medical) was cleared for marketing by the U.S. Food and Drug Administration through the 510(k) process for treatment of various spinal conditions. This set of specialized surgical instruments is used to perform percutaneous lumbar decompressive procedures.

Vertos's mild® instructions state that the device is not intended for disc procedures but rather for tissue resection at the perilaminar space, within the interlaminar space, and at the ventral aspect of the lamina. The device is not intended for use near the lateral neural elements and remains dorsal to the dura using image guidance and anatomic landmarks.

U.S. Food and Drug Administration product code: HRX.

### POLICY STATEMENT

Image-guided minimally invasive spinal decompression is considered **investigational**.

### BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

---

**FEP 7.01.126 Image-Guided Minimally Invasive Lumbar Decompression for Spinal Stenosis**

---

**RATIONALE****Summary of Evidence**

For individuals who have lumbar spinal stenosis or cervical or thoracic spinal stenosis who receive IG-MLD, the evidence includes a large, ongoing randomized controlled trial (N=302), a systematic review of a small randomized controlled trial (N=38), and a number of prospective and retrospective cohort studies and case series. Relevant outcomes are symptoms, functional outcomes, health status measures, and treatment-related morbidity. The largest randomized controlled trial compared IG-MLD with epidural steroid injections (control) in patients who had ligamentum flavum hypertrophy and who failed conservative therapy. Early results have suggested reductions in pain and improvements in function scores in the IG-MLD group vs the control group. The trial was unblinded and there is evidence of differing expectations and follow-up in the two groups, suggesting a high risk of bias. The available evidence is insufficient to determine the efficacy of mild® compared with placebo or to determine the efficacy of IG-MLD compared with open decompression. Trials with relevant control groups could provide greater certainty on the risks and benefits of this procedure. The evidence is insufficient to determine the effects of the technology on health outcomes.

**SUPPLEMENTAL INFORMATION****Practice Guidelines and Position Statements**

No guidelines or statements were identified.

**U.S. Preventive Services Task Force Recommendations**

Not applicable.

**Medicare National Coverage**

Effective for services performed on or after January 9, 2014, the Centers for Medicare & Medicaid Services has determined that percutaneous image-guided lumbar decompression for lumbar spinal stenosis is not reasonable and necessary.<sup>12</sup>

The Centers for Medicare & Medicaid Services determined that percutaneous image-guided lumbar decompression would be covered by Medicare when provided in a clinical study through coverage with evidence development for beneficiaries with lumbar spinal stenosis enrolled in an approved clinical study meeting criteria in the decision memo.

According to the national coverage decision, percutaneous image-guided lumbar decompression is a posterior decompression of the lumbar spine performed under indirect image guidance without any direct visualization of the surgical area. This procedure is proposed as a treatment for symptomatic lumbar spinal stenosis unresponsive to conservative therapy. This procedure is generally described as a noninvasive procedure using specially designed instruments to percutaneously remove a portion of the lamina and debulk the ligamentum flavum. The procedure is performed under x-ray guidance (eg, fluoroscopic, computed tomography) with contrast media to identify and monitor the compressed area via epidurogram.

**REFERENCES**

1. Chou R, Baisden J, Carragee EJ, et al. Surgery for low back pain: a review of the evidence for an American Pain Society Clinical Practice Guideline. *Spine*. May 1 2009;34(10):1094-1109. PMID 19363455
2. Chou R, Loeser JD, Owens DK, et al. Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. *Spine*. May 1 2009;34(10):1066-1077. PMID 19363457

## FEP 7.01.126 Image-Guided Minimally Invasive Lumbar Decompression for Spinal Stenosis

3. Weinstein JN, Lurie JD, Tosteson TD, et al. Surgical versus nonsurgical treatment for lumbar degenerative spondylolisthesis. *N Engl J Med*. May 31 2007;356(22):2257-2270. PMID 17538085
4. Weinstein JN, Tosteson TD, Lurie JD, et al. Surgical versus nonsurgical therapy for lumbar spinal stenosis. *N Engl J Med*. Feb 21 2008;358(8):794-810. PMID 18287602
5. Staats PS, Benyamin RM. MiDAS ENCORE: randomized controlled clinical trial report of 6-month results. *Pain Physician*. Feb 2016;19(2):25-38. PMID 26815247
6. Benyamin RM, Staats PS, Mi DASEI. MiDAS ENCORE: randomized controlled trial. *Pain Physician*. May 2016;19(4):229-242. PMID 27228511
7. Kreiner DS, Macvicar J, Duszynski B, et al. The mild(R) Procedure: a systematic review of the current literature. *Pain Med*. Feb 2014;15(2):196-205. PMID 24308292
8. Brown LL. A double-blind, randomized, prospective study of epidural steroid injection vs. the mild(R) procedure in patients with symptomatic lumbar spinal stenosis. *Pain Pract*. Jun 2012;12(5):333-341. PMID 22272730
9. Chopko BW. Long-term results of percutaneous lumbar decompression for LSS: two-year outcomes. *Clin J Pain*. Nov 2013;29(11):939-943. PMID 23446067
10. Chopko BW. A novel method for treatment of lumbar spinal stenosis in high-risk surgical candidates: pilot study experience with percutaneous remodeling of ligamentum flavum and lamina. *J Neurosurg Spine*. Jan 2011;14(1):46-50. PMID 21142460
11. Lingreen R, Grider JS. Retrospective review of patient self-reported improvement and post-procedure findings for mild (minimally invasive lumbar decompression). *Pain Physician*. Nov-Dec 2010;13(6):555-560. PMID 21102968
12. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for percutaneous image-guided lumbar decompression for lumbar spinal stenosis (150.13). 2014; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=358&ncdver=1&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=All&Keyword=decompression&KeywordLookup=Title&KeywordSearchType=And&bc=gAAAAABAAAAA>. Accessed March 8, 2018.

### POLICY HISTORY

Date	Action	Description
December 2011	New Policy	
June 2013	Update Policy	Policy updated with literature review, references added, reordered and renumbered. No change in policy statement.
September 2014	Update Policy	Policy updated with literature review; references 5-6 added. Policy statement unchanged.
June 2018	Update Policy	Policy updated with literature review through February 5, 2018; no references added. Policy statement changed from medically necessary for central stenosis without nerve root compression or disc herniation to investigational for all conditions.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.